- Invion is advancing research & development of PhotosoftTM technology for treating a range of cancers, atherosclerosis, and infectious diseases.
- Invion’s new API, INV043 successfully regressed multiple tumour types including established T-cell lymphoma, triple-negative breast, and pancreatic cancers in vivo.
- Latest PoC pilot studies indicate complete regression of triple-negative breast cancer, a hard-to-treat cancer, in mice. Results have indicated no scarring after two weeks and development of protective immunity.
- The Company is also focused on developing Photosoft™ technology to meet demand in the atherosclerosis and infectious diseases (AID) space.
Clinical-stage life sciences firm Invion Limited (ASX:IVX) is targeting the treatment of several diseases, including a range of cancers, on the back of its global research & development of PhotosoftTM technology.
Notably, the Company holds the Australia and New Zealand licence and distribution rights to the PhotosoftTM technology, which is being developed as the next-generation Photodynamic Therapy (PDT).
Also, recently, the Company expanded its existing agreement with RMW Cho Group Limited to co-develop Photosoft™ technology for cancer and related diseases. The move expands its addressable markets, which include all Asia-Pacific countries excluding China, Macau, Taiwan, Japan, and South Korea.
Following extensive research & development, the Company selected the new Active Pharmaceutical Ingredient (API)- INV043, which has shown superior anti-cancer activity across a wide array of cancers in the initial proof-of-concept studies.
With this backdrop, let us explore the treatment space where the Company is eyeing to widen its footprint.
Triple-negative breast cancer
Triple-negative breast cancer is a hard-to-treat cancer that is resistant to most chemotherapies. It represents one of many cancer types where a strong clinical need exists for alternatives to current standard of care.
As TNBC does not have any receptors for hormones-progesterone and estrogen, it does not respond to hormonal therapy. As a result, it requires combined surgery.
Invion’s INV043 has the potential to address the unmet market needs to replace surgery and can prove to be an effective solution to overcome the current challenges in treating breast cancer.
Latest PoC pilot studies indicate complete regression of TNBC in vivo, using INV043 to treat immunocompetent mice. Results show that tumour mass was undetectable two weeks after initial treatment, with no scarring evident.
Moreover, TNBC implant could not re-establish new tumours when re-challenged with TNBC. It suggests the development of protective immunity.
Exposure to high-average annual radiation and risk of lymphoma associated with autoimmune disorders have proven to be significant drivers of T-cell lymphoma incidences over the past couple of years.
Meanwhile, increasing estimated deaths due to T-cell lymphoma are also expected to contribute to the growth of the global T-cell lymphoma market.
While there have been significant growth trends, adverse side effects of therapies continue to remain an essential issue for the healthcare industry.
In this context, Invion’s PhotosoftTM technology, which is not immunosuppressive, seems to be in a sweet spot to make a mark in the T-cell lymphoma treatment space.
The POC studies undertaken in May 2021 showed significant action of INV043 on T-cell lymphoma, with the phototoxicity (IC90) of merely 30nM. Notably, IC90 represents the concentration required to kill 90% of cells.
Pancreatic cancer model
The treatment of pancreatic cancer is often hindered by delayed detection of the disease, lack of effective therapies, rapid progression, and poor survival outcomes. As a result of poor survival outcomes, the market consumption continues to shift from chemotherapy to adopting other treatment techniques.
It can provide a significant opportunity to INV043, which has demonstrated positive results in the initial proof-of-concept test studies.
Atherosclerosis and infectious diseases (AID)
Invion has also advanced in the treatment area of atherosclerosis and infectious diseases under its agreement with RMW Cho. Under the arrangement, the Companies would co-develop the Photosoft™ technology for treating atherosclerosis and infectious viral, bacterial, parasitic, and fungal diseases.
Source: Copyright © 2021 Kalkine Media, Data Source: IVX Presentation, dated 9 November 2021
All in all, Invion is rapidly progressing towards the commercialisation of the next-generation PDT treatment for major diseases.
IVX shares were trading at AU$0.018 midday on 30 November 2021.